Hibercell

Developer of therapeutics for the treatment of solid and liquid cancers

placeNew York City, New York, United States calendar_todayFounded 2015 groups53 employees language hibercell.com

Innovation

32 patent families (14 granted) — focus: Chemistry & metallurgy, Human necessities, Physics & computing; filing pace steady. Cited 1,460 times.

YearFilings
20191
20206
202112
202214
202310
202413
202513
20262

Social engagement

Social engagement: 3.4K social following, 3 posts in the last 12 months — above the industry median.

Investor mix

11 investors on record; lead investors include Monashee Investment Management, Hercules Capital, Mount Sinai, Arch Venture Partners.

Investor typeCountShare
Venture capital327%
Private equity19%
Bank & private debt19%
Other / undisclosed655%

Recent activity

21 May 2026
Event
2026 ASCO Annual Meeting
14 Apr 2026
Event
AACR Annual Meeting 2026
6 Nov 2025
Partnership
AVEO Oncology
Coming soon